<DOC>
	<DOCNO>NCT02650713</DOCNO>
	<brief_summary>This open-label , multi-center , dose escalation expansion Phase IB clinical study RO6958688 combination atezolizumab .</brief_summary>
	<brief_title>A Study Safety , Pharmacokinetics , Therapeutic Activity RO6958688 Combination With Atezolizumab Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen ( CEA ) -Positive Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Confirmed locally advance and/or metastatic solid tumor participant progressed standard therapy , intolerant standard therapy , and/or nonamenable standard therapy Life expectancy ( opinion investigator ) &gt; = 12 week Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) 01 All acute toxic effect prior radiotherapy , chemotherapy , surgical procedure must resolve Grade &lt; = 1 returned baseline , except alopecia ( grade ) Grade 2 peripheral neuropathy Adequate hematological , liver , renal function Negative serum pregnancy test within 7 day prior study treatment premenopausal woman woman &lt; = 2 year start menopause For woman childbearing potential : agreement remain abstinent ( refrain heterosexual intercourse ) use contraceptive method result failure rate &lt; 1 % per year treatment period least 90 day last dose study drug Locally confirm CEA expression tumor tissue Active untreated central nervous system ( CNS ) metastasis determine compute tomography ( CT ) magnetic resonance imaging ( MRI ) evaluation screen prior radiographic assessment Spinal cord compression definitively treat surgery and/or radiation previously diagnose treat spinal cord compression without evidence disease clinically stable &gt; = 2 week prior enrollment Leptomeningeal disease Malignancies nonsmallcell lung cancer ( NSCLC ) within 5 year prior enrollment , exception negligible risk metastasis death treat expect curative outcome ( adequately treat carcinoma situ cervix , basal squamous cell skin cancer , localize prostate cancer treat surgically curative intent , ductal carcinoma situ treat surgically curative intent ) Significant , uncontrolled concomitant disease could affect compliance protocol interpretation result , include diabetes mellitus , pulmonary disorder , know autoimmune disease Uncontrolled hypertension ( systolic blood pressure ( BP ) &gt; 150 mmHg and/or diastolic BP &gt; 100 mmHg ) , unstable angina , congestive heart failure ( CHF ) New York Heart Association ( NYHA ) classification ( Class II great ) , serious cardiac arrhythmia require treatment ( exception : atrial fibrillation , paroxysmal supraventricular tachycardia ) , history myocardial infarction within 6 month enrollment Administration live , attenuate vaccine within 28 day Day 1 anticipation live attenuated vaccine require study Known HIV Active Hepatitis B ( HBV ) Hepatitis C ( HCV ) infection ( require screening ) Severe infection within 28 day prior Day 1 , include , limited hospitalization complication infection , bacteremia , severe pneumonia active tuberculosis Received oral intravenous ( IV ) antibiotic within 14 day prior Day 1 ( Patients receive prophylactic antibiotic ( e.g. , prevention urinary tract infection ) eligible ) Any disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition would contraindicate use investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>